MedTrace Logo

One-Year Study of S1B-509 vs Placebo for Weight Loss

NCT06517797 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-06-18

No results posted yet for this study

Summary

This is a study to test whether S1B-509 given orally daily helps people with overweight or obesity to lose more weight than with placebo over a year.

Conditions

Interventions

DRUG

S1B-509 low dose

S1B-509 has multiple neurotransmitter activities

DRUG

Placebo

matched pills to S1B-509

DRUG

S1B-509 High Dose

S1B-509 has multiple neurotransmitter activities

Sponsors & Collaborators

  • S1 Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicolas E Sitchon, B.S. · S1 Biopharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2027-06-15
Completion
2027-12-15
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06517797 on ClinicalTrials.gov